BOSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. INZY (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, highlighted the inclusion of Generalized Arterial Calcification of Infancy (GACI), which is caused by mutations in the…Read More
Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy GACI in Genomics Englands Generation Study of Rare Conditions Inozyme Pharma NASDAQINZY
